Aerovate Therapeutics, Inc. (AVTE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AVTE Stock Price Chart Interactive Chart >
AVTE Price/Volume Stats
|Current price||$22.85||52-week high||$30.79|
|Prev. close||$23.69||52-week low||$8.33|
|Day high||$24.23||Avg. volume||90,635|
|50-day MA||$23.51||Dividend yield||N/A|
|200-day MA||$18.58||Market Cap||557.77M|
Aerovate Therapeutics, Inc. (AVTE) Company Bio
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Most Popular Stories View All
AVTE Latest News Stream
|Loading, please wait...|
AVTE Latest Social Stream
View Full AVTE Social Stream
Latest AVTE News From Around the Web
Below are the latest news stories about AEROVATE THERAPEUTICS INC that investors may wish to consider to help them evaluate AVTE as an investment opportunity.
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are ex
In this article we are going to estimate the intrinsic value of Aerovate Therapeutics, Inc. ( NASDAQ:AVTE ) by taking...
In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]
Aerovate Therapeutics Inc. (NASDAQ:AVTE) Declines -135.40% In 2022; Are Investors Attracted By Its $26.00 Price?
In last trading session, Aerovate Therapeutics Inc. (NASDAQ:AVTE) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $26.00 trading at $0.35 or 1.36% at ring of the bell on the day assigns it a market valuation of $627.64M. That closing price of AVTE’s stock is … Aerovate Therapeutics Inc. (NASDAQ:AVTE) Declines -135.40% In 2022; Are Investors Attracted By Its $26.00 Price? Read More »
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) fell 23% to $8.31. The Lion Electric Company (NYSE: LEV ) declined 14.5% to $2.2810. Lion Electric reported pricing of 19,685,040 unit offering at $2.54 per unit. Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) dropped 11.5% to $27.00. Aerovate Therapeutics, last month, posted a Q3 loss of $0.56 per share. Nikola Corporation (NASDAQ: NKLA ) … Full story available on Benzinga.com
AVTE Price Returns